A retrospective, multicenter study to evaluate Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer
Latest Information Update: 20 Feb 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 01 Feb 2023 Results assessing the relationship of previous thoracic radiation therapy with immune-related pneumonitis and the characteristics of radiation recall pneumonitis, published in the Cancer Science.
- 15 Feb 2020 New trial record